[Funding News] PA-based Coeptis Therapeutics Secures $4.3 Mn Series A Funding

Coeptis Therapeutics Holdings, a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases has secured $4.3 million funding led by CJC Investment Trust, an entity controlled by board member Christopher Calise. Proceeds from this financing will be allocated towards repayment of outstanding obligations, working capital, and general corporate purposes.

Read also – [Funding News] CA-based āshibio Raises $40M Seed and Series A Financing

Under the terms of the financing, the Series A Preferred is convertible into shares of the Company’s common stock at a price of $0.40 per share, subject to limitations. The investors also received in the aggregate a 6.45% equity interest in two of the Company’s newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.

Read also – [Funding News] CA-based GrayMatter Raises $45M Series B Funding

Dave Mehalick, President and CEO of Coeptis Therapeutics said, “We are grateful for the continued support from our investors, particularly in these transformative times for Coeptis Therapeutics. These individuals share our passion and long-term vision for Coeptis, and their support goes beyond investment, reflecting a focus on the Company’s future.”

“This financing comes at an opportune moment as we are anticipating several significant near-term milestones. The commitment from our investors not only strengthens our balance sheet but also bolsters our innovative cell therapy platforms and long-term growth prospects.”

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a clinical stage biotechnology company developing innovative cell therapy platforms for patients with cancer and other debilitating diseases. Coeptis was founded in 2017 and is headquartered in Wexford, PA.